L
Lalji K. Gediya
Researcher at University of Maryland, Baltimore
Publications - 35
Citations - 1441
Lalji K. Gediya is an academic researcher from University of Maryland, Baltimore. The author has contributed to research in topics: Cancer & Histone deacetylase inhibitor. The author has an hindex of 19, co-authored 35 publications receiving 1296 citations. Previous affiliations of Lalji K. Gediya include University of Mumbai & University of Maryland Marlene and Stewart Greenebaum Cancer Center.
Papers
More filters
Journal ArticleDOI
Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens: Synthesis, in Vitro Biological Activity, Pharmacokinetics, and Antitumor Activity in the LAPC4 Human Prostate Cancer Xenograft Model
Venkatesh D. Handratta,Tadas S. Vasaitis,Vincent C. O. Njar,Lalji K. Gediya,Ritesh Kataria,Pankaj Chopra,Donnell Newman,Rena Farquhar,Zhiyong Guo,Yun Qiu,Angela Brodie +10 more
TL;DR: To the authors' knowledge, this is the first example of an antihormonal agent (an inhibitor of androgen synthesis (CYP17 inhibitor)/antiandrogen) that is significantly more effective than castration in suppression of androgens-dependent prostate tumor growth.
Journal ArticleDOI
Promise and challenges in drug discovery and development of hybrid anticancer drugs
TL;DR: In the era of increasing drug resistance in cancer patients, the discovery of hybrid drugs could provide an effective strategy to create chemical entities likely to be more efficacious and less prone to resistance.
Journal ArticleDOI
Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases.
Vincent C. O. Njar,Lalji K. Gediya,Lalji K. Gediya,Puranik Purushottamachar,Puranik Purushottamachar,Pankaj Chopra,Pankaj Chopra,Tadas S. Vasaitis,Tadas S. Vasaitis,Aakanksha Khandelwal,Aakanksha Khandelwal,Jhalak Mehta,Jhalak Mehta,Carlic Huynh,Carlic Huynh,Aashvini Belosay,Aashvini Belosay,Jyoti Patel,Jyoti Patel +18 more
TL;DR: A novel strategy to overcome the limitation associated with exogenous ATRA therapy has been to modulate and/or increase the levels of endogenous ATRA by inhibiting the cytochrome P450-dependent ATRA-4-hydroxylase enzymes (particularly CYP26s) responsible for ATRA metabolism.
Journal ArticleDOI
Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.
Puranik Purushottamachar,Abhijit M. Godbole,Lalji K. Gediya,Marlena S. Martin,Tadas S. Vasaitis,Tadas S. Vasaitis,Andrew K. Kwegyir-Afful,Senthilmurugan Ramalingam,Zeynep Ates-Alagoz,Zeynep Ates-Alagoz,Vincent C. O. Njar +10 more
TL;DR: It is discovered that compounds prepared, including 5, 36, 43, and 47, could degrade both full-length and truncated ARs in CWR22rv1 human prostate cancer cells and have potential for development as new drugs for the treatment of all forms of prostate cancer.
Journal ArticleDOI
A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells.
TL;DR: SAHA is a potent inhibitor of histone deacetylase, induces differentiation and/or apoptosis in certain transformed cells in culture, and suppressed the growth of human prostate cancer LNCaP and PC-3 cell lines.